LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Search

10X Genomics Inc (Class A)

Закрыт

СекторЗдравоохранение

15.43 -6.65

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

15.35

Макс.

15.62

Ключевые показатели

By Trading Economics

Доход

-62M

-27M

Продажи

-24M

149M

Прибыль на акцию

0.28

Рентабельность продаж

-18.437

Сотрудники

1,306

EBITDA

-63M

-16M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+9.25% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

505M

2.2B

Предыдущая цена открытия

22.08

Предыдущая цена закрытия

15.43

Новостные настроения

By Acuity

50%

50%

158 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Bullish Evidence

10X Genomics Inc (Class A) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

14 дек. 2025 г., 22:53 UTC

Приобретения, слияния, поглощения

Fortescue to Take Full Control of US$101 Million Copper Miner Alta

13 дек. 2025 г., 00:04 UTC

Приобретения, слияния, поглощения

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6 Billion, Bloomberg Reports, Citing Sources

14 дек. 2025 г., 23:46 UTC

Обсуждения рынка

Gold Edges Higher Amid Some Tailwinds -- Market Talk

14 дек. 2025 г., 23:36 UTC

Обсуждения рынка

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

14 дек. 2025 г., 22:38 UTC

Приобретения, слияния, поглощения

Fortescue to Take Full Control of US$101M Copper Miner Alta

14 дек. 2025 г., 22:02 UTC

Приобретения, слияния, поглощения

Fortescue: Transaction Is Consistent With Critical Minerals Strategy

14 дек. 2025 г., 22:01 UTC

Приобретения, слияния, поглощения

Fortescue: Alta Owns the Canariaco Project in Northern Peru

14 дек. 2025 г., 22:01 UTC

Приобретения, слияния, поглощения

Fortescue: Alta Directors Unanimously Recommend Proposal, Will Vote in Favor

14 дек. 2025 г., 22:00 UTC

Приобретения, слияния, поглощения

Fortescue: Agreement Implies Total Equity Value of C$139 Million

14 дек. 2025 г., 22:00 UTC

Приобретения, слияния, поглощения

Fortescue to Pay C$1.40/Share for Securities It Does Not Already Own

14 дек. 2025 г., 21:59 UTC

Приобретения, слияния, поглощения

Fortescue to Acquire Remaining 64% of Alta Copper

14 дек. 2025 г., 17:00 UTC

Отчет

Tonka Trucks Gambled on Keeping Production in China and Survived -- Barely -- WSJ

14 дек. 2025 г., 08:30 UTC

Приобретения, слияния, поглощения

Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. -- Barrons.com

13 дек. 2025 г., 16:48 UTC

Приобретения, слияния, поглощения

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 дек. 2025 г., 08:00 UTC

Приобретения, слияния, поглощения

How the War to Win Warner Bros. Discovery Will Be Won -- Barrons.com

13 дек. 2025 г., 07:00 UTC

Приобретения, слияния, поглощения

A Chubb/AIG Deal Could Be Good for Shareholders and a Coup for Greenberg Family -- Barrons.com

13 дек. 2025 г., 00:24 UTC

Приобретения, слияния, поглощения

Want a Piece Of SpaceX? -- Barrons.com

12 дек. 2025 г., 23:49 UTC

Приобретения, слияния, поглощения

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12 дек. 2025 г., 22:52 UTC

Обсуждения рынка

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12 дек. 2025 г., 22:32 UTC

Отчет

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

12 дек. 2025 г., 20:45 UTC

Отчет

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12 дек. 2025 г., 20:41 UTC

Обсуждения рынка

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12 дек. 2025 г., 20:20 UTC

Обсуждения рынка

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12 дек. 2025 г., 19:23 UTC

Отчет

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12 дек. 2025 г., 18:35 UTC

Приобретения, слияния, поглощения

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12 дек. 2025 г., 18:33 UTC

Приобретения, слияния, поглощения

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12 дек. 2025 г., 18:31 UTC

Обсуждения рынка

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12 дек. 2025 г., 17:49 UTC

Отчет

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12 дек. 2025 г., 17:34 UTC

Приобретения, слияния, поглощения

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

Сравнение c конкурентами

Изменение цены

10X Genomics Inc (Class A) Прогноз

Целевая цена

By TipRanks

9.25% рост

Прогноз на 12 месяцев

Средняя 16.89 USD  9.25%

Максимум 20 USD

Минимум 14 USD

Основано на мнении 11 аналитиков Wall Street, спрогнозировавших целевые цены для 10X Genomics Inc (Class A) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

11 ratings

3

Покупка

8

Удержание

0

Продажа

Техническая оценка

By Trading Central

8.32 / 8.63Поддержка и Сопротивление

Краткосрочная

Bullish Evidence

Среднесрочная

Bullish Evidence

Долгосрочная

No Evidence

Настроения

By Acuity

158 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat